BioSpecifics Technologies (BSTC) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of BioSpecifics Technologies (NASDAQ:BSTC) from a strong sell rating to a sell rating in a research note published on Saturday morning.

Several other research analysts have also weighed in on BSTC. HC Wainwright reiterated a buy rating and issued a $65.00 price objective on shares of BioSpecifics Technologies in a research note on Tuesday, March 13th. Zacks Investment Research upgraded shares of BioSpecifics Technologies from a hold rating to a buy rating and set a $47.00 price objective on the stock in a research note on Friday, March 16th.

How to Become a New Pot Stock Millionaire

BSTC stock opened at $43.13 on Friday. The firm has a market cap of $310.50, a P/E ratio of 25.37 and a beta of 1.55. BioSpecifics Technologies has a 12 month low of $38.05 and a 12 month high of $58.79.

A number of institutional investors have recently added to or reduced their stakes in BSTC. Dimensional Fund Advisors LP increased its stake in shares of BioSpecifics Technologies by 1.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 269,554 shares of the biopharmaceutical company’s stock worth $12,540,000 after purchasing an additional 3,878 shares during the last quarter. First Quadrant L P CA increased its stake in shares of BioSpecifics Technologies by 52.7% during the 4th quarter. First Quadrant L P CA now owns 11,631 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 4,015 shares during the last quarter. Royce & Associates LP increased its stake in shares of BioSpecifics Technologies by 21.6% during the 4th quarter. Royce & Associates LP now owns 48,038 shares of the biopharmaceutical company’s stock worth $2,081,000 after purchasing an additional 8,521 shares during the last quarter. Stonepine Capital Management LLC increased its stake in shares of BioSpecifics Technologies by 82.6% during the 4th quarter. Stonepine Capital Management LLC now owns 385,954 shares of the biopharmaceutical company’s stock worth $16,723,000 after purchasing an additional 174,584 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of BioSpecifics Technologies by 99.0% during the 4th quarter. SG Americas Securities LLC now owns 6,911 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 3,438 shares during the last quarter. Hedge funds and other institutional investors own 56.57% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BioSpecifics Technologies (BSTC) Stock Rating Upgraded by BidaskClub” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3298974/biospecifics-technologies-bstc-stock-rating-upgraded-by-bidaskclub.html.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

UNCoin  Market Cap Reaches $0.00
UNCoin Market Cap Reaches $0.00
$1.52 EPS Expected for Texas Capital Bancshares, Inc.  This Quarter
$1.52 EPS Expected for Texas Capital Bancshares, Inc. This Quarter
I/O Coin Trading 0.3% Higher  This Week
I/O Coin Trading 0.3% Higher This Week
Head-To-Head Contrast: PennantPark Floating Rate  versus Safeguard Scientifics
Head-To-Head Contrast: PennantPark Floating Rate versus Safeguard Scientifics
$0.55 EPS Expected for American Water  This Quarter
$0.55 EPS Expected for American Water This Quarter
Wintrust Financial Co.  Expected to Post Quarterly Sales of $325.50 Million
Wintrust Financial Co. Expected to Post Quarterly Sales of $325.50 Million


© 2006-2018 Ticker Report. Google+.